Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Optiscan Imaging (ASX: OIL) Launches Second Cancer Trial: Why This MedTech Stock Looks Like a Buy

Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch Australia's first-in-human head and neck cancer imaging study. The ground-breaking study will recruit 50 patients at the St John of God Healthcare campus in Murdoch and will be led by prominent Perth head and neck cancer surgeon Dr Chady Sader. For investors tracking…

ByUjjwal MaheshwariDecember 4, 2025

Epiminder (ASX: EPI) Makes ASX Debut After Raising $125M for FDA-Approved Epilepsy Device

Epiminder (ASX: EPI) made its ASX debut on Monday after raising $125 million at $1.50 per share, giving the company a market capitalisation of approximately $325 million. The Melbourne-based medtech is backed by hearing implant giant Cochlear (ASX: COH), which holds a 36% stake following the listing. For investors, the critical question now is whether…

ByUjjwal MaheshwariDecember 2, 2025

Paragon Care Acquires Haju Medical for $70M as Asia Aesthetics Push Accelerates

Paragon Care (ASX: PGC) is betting big on Asia. The healthcare distributor, currently trading near its 52-week lows around $0.29, has struck a $70 million deal to acquire Haju Medical, an Indonesian aesthetics business that sells devices and injectables to dermatologists and cosmetic surgeons. This is the company's second acquisition in just four weeks, signalling…

ByUjjwal MaheshwariDecember 2, 2025

Mayne Pharma Collapses 30% as Treasurer Flags National-Interest Block in Cosette Deal

Mayne Pharma in Freefall: Regulatory Hurdle Threatens $672 m Buy-out Mayne Pharma (ASX: MYX) has suddenly become one of the most talked-about stocks on the ASX after the federal Treasurer raised serious national-interest concerns about its proposed takeover by Cosette Pharmaceuticals. The company that looked like it was on the cusp of being acquired is now…

ByCharlie YouldenOctober 31, 2025

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer

$100bn biotechs like Vertex Pharmaceuticals (NDQ:VRTX) typically get to their position through 'blockbuster drugs' with periods of market exclusivity, which eventually come to an end and cause revenues to fall as cheaper biosimilars come onto the market. The average biotech is facing a loss of revenue of 38%. Of course, some are higher (i.e. Amgen…

ByNick SundichOctober 23, 2025

Genetic Signatures (ASX: GSS) Soars 47% on Record Quarterly Sales

Record Sales Drive 47% Surge in Genetic Signatures Shares Genetic Signatures (ASX: GSS) caught the market’s attention today, surging 47% after releasing a quarterly update that marked a major turning point. The company reported record sales of A$5.4 million for Q1 FY2026, up 20% from the previous quarter and 15% year-on-year its strongest performance since…

ByCharlie YouldenOctober 21, 2025

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

There's a Biotech Patent Cliff coming over the next decade! Investors aren't giving this much attention, but we think they should because it could cause substantial upheaval in the biotech sector. What are the Best ASX Life Sciences Stocks to invest in right now? Check our buy/sell tips What is this 'patent cliff'? A patent cliff in…

ByNick SundichOctober 21, 2025

Telix Pharmaceuticals (ASX: TLX) Stages a Comeback as FY25 Update Signals Renewed Momentum

Telix Pharmaceuticals (ASX: TLX) has been one of Australia’s most talked-about biotech stories ... a company that once soared on excitement, stumbled through FDA delays and accounting scrutiny, and is now showing early signs of revival. After a turbulent stretch that tested investor patience, the company has released its FY25 (ending December) guidance, and the…

ByCharlie YouldenOctober 15, 2025

Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?

The dream run Pfizer had during the pandemic was not going to last forever. But while certain companies that derived a windfall during the pandemic (one example being Sonic (ASX:SHL)) had decent businesses pre-COVID and began to 'normalise' post-pandemic, Pfizer has continued to decline (shares have dropped another 12% in 2025). What are the Best ASX…

ByNick SundichOctober 13, 2025

Mesoblast (ASX:MSB): Which direction will this rollercoaster of a $3bn biotech company go next?

Biotech company Mesoblast (ASX:MSB) is the ultimate definition of a rollercoaster company. As of October 7, 2025, it is capped at $3.2bn, which makes it the third largest 'biotech' behind CSL and Telix (note: we're just talking biotechs, not healthcare stocks more broadly - although if you include all healthcare stocks, MSB still makes the…

ByNick SundichOctober 9, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Optiscan Imaging (ASX: OIL) Launches Second Cancer Trial: Why This MedTech Stock Looks Like a Buy

Epiminder (ASX: EPI) Makes ASX Debut After Raising $125M for FDA-Approved Epilepsy Device

Paragon Care Acquires Haju Medical for $70M as Asia Aesthetics Push Accelerates

Mayne Pharma Collapses 30% as Treasurer Flags National-Interest Block in Cosette Deal

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer

Genetic Signatures (ASX: GSS) Soars 47% on Record Quarterly Sales

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

Telix Pharmaceuticals (ASX: TLX) Stages a Comeback as FY25 Update Signals Renewed Momentum

Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?

Mesoblast (ASX:MSB): Which direction will this rollercoaster of a $3bn biotech company go next?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here